Search results
Find the latest Alzamend Neuro, Inc. (ALZN) stock quote, history, news and other vital information to help you with your stock trading and investing.
- Chart
Interactive Chart for Alzamend Neuro, Inc. (ALZN), analyze...
- Profile
See the company profile for Alzamend Neuro, Inc. (ALZN)...
- News
The latest news and headlines from Yahoo News. Get breaking...
- Holders
Find out the direct holders, institutional holders and...
- Statistics
Find out all the key statistics for Alzamend Neuro, Inc....
- Chart
2 dni temu · On Wednesday, Alzamend Neuro, Inc. (NASDAQ:ALZN) said it received the final full data set from its multiple ascending dose clinical trial for AL001 for dementia related to Alzheimer's. Preliminary ...
2 dni temu · ATLANTA--(BUSINESS WIRE)-- Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease (“Alzheimer’s”), bipolar disorder (“BD”), major depressive disorder (“MDD”) and post-traumatic stress disorder (“PTSD ...
4 dni temu · Get a real-time Alzamend Neuro, Inc. (ALZN) stock price quote with breaking news, financials, statistics, charts and more.
4 dni temu · Earlier this year, Alzamend entered into a securities purchase agreement to provide for the sale of $25 million of Alzamend's Series A Convertible Preferred Stock ("Series A Preferred") over a period of time. To date, the investor has purchased $8 million of Series A Preferred, with (i) an additional $2 million to be funded within the next 30 ...
10 paź 2024 · We initiated the Phase I/IIA clinical trial in March 2023. Alzamend Neuro® , Inc., (“Alzamend® ”), a Delaware corporation with its headquarters in Atlanta, Georgia, is a clinical-stage, biopharmaceutical company.
3 dni temu · ATLANTA--(BUSINESS WIRE)--Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s ...